Archives of the Turkish Society of Cardiology
Cardiac scintigraphy-centered diagnostic process in transthyretin cardiac amyloidosis [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2020; 48(5): 514-521 | DOI: 10.5543/tkda.2020.90914

Cardiac scintigraphy-centered diagnostic process in transthyretin cardiac amyloidosis

Ilknur Ak Sivrikoz1, Yüksel Çavuşoğlu2
1Department of Nuclear Medicine, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey
2Department of Cardiology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey

Cardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy. Amyloid fibrils in the form of misfolded endogenous proteins accumulate in the heart, as well as the kidneys, liver, and gastrointestinal tract. The most common forms of CA are transthyretin (TTR) and immunoglobulin light chain amyloidosis (AL). CA has long been thought to be a rare disease. However, recent reports have suggested that 13% of heart failure patients with a preserved ejection fraction and 16% of advanced-age patients with severe aortic stenosis have TTR-CA. Patients with TTR-CA have a poor prognosis, with a median survival of 2–4 years; however, early diagnosis and novel therapeutic options have been shown to significantly improve the prognosis. Scintigraphy using bone isotopes is considered a highly reliable and easy-to-use method in the diagnosis of TTR-CA. This is a review of the role of scintigraphic imaging with technetium-99m- labeled bisphosphonates in the diagnostic work-up process of TTR-CA and the applicable protocols.

Keywords: Cardiac amyloidosis, bone scintigraphy; diagnosis.

How to cite this article
Ilknur Ak Sivrikoz, Yüksel Çavuşoğlu. Cardiac scintigraphy-centered diagnostic process in transthyretin cardiac amyloidosis. Turk Kardiyol Dern Ars. 2020; 48(5): 514-521

Corresponding Author: Yüksel Çavuşoğlu, Türkiye
© Copyright 2020 Archives of the Turkish Society of Cardiology
LookUs & Online Makale